Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients

Summary

This is a randomized, double-blind, vehicle-controlled, parallel-group comparison study to evaluate the safety and efficacy of Q301 Cream vs. vehicle in adult subjects with moderate to severe AD. Study drug (Q301 Cream or vehicle) will be administered topically twice a day for 8 consecutive weeks.

Timeline

Start

2015-04

Primary completion

2016-01

Completion

2016-05

Drugs

Indications